Related Experiment Videos
[Central nervous system involvement in Behçet's disease]
1Department of Internal Medicine, Teikyo University School of Medicine.
Rinsho Shinkeigaku = Clinical Neurology
|September 19, 2002
Summary
Behçet's disease can affect the central nervous system, causing acute or chronic neuro-Behçet's syndrome (NB). Chronic NB, often linked to HLA-B51, shows progressive neurological decline and may benefit from low-dose methotrexate.
Area of Science:
- Neurology
- Immunology
- Rheumatology
Context:
- Behçet's disease is a multisystem inflammatory disorder.
- Central nervous system involvement, termed neuro-Behçet's syndrome (NB), presents in acute and chronic forms.
- Understanding the distinct characteristics and treatment responses of these NB types is crucial.
Purpose:
- To differentiate between acute and chronic neuro-Behçet's syndrome.
- To highlight the clinical features, diagnostic markers, and treatment outcomes for each NB type.
- To explore potential therapeutic strategies for refractory chronic NB.
Summary:
- Acute NB involves meningoencephalitis with focal MRI lesions, often triggered by Cyclosporin A, and typically responds to steroids.
- Chronic progressive NB is characterized by progressive dementia and ataxia, associated with elevated cerebrospinal fluid IL-6 and HLA-B51 positivity in most cases.
- Chronic NB is generally resistant to standard immunosuppressants, but emerging evidence suggests efficacy of low-dose methotrexate.
Impact:
- Provides a clear distinction between acute and chronic NB, aiding in diagnosis and management.
- Identifies key clinical and laboratory markers (CSF IL-6, HLA-B51) for diagnosing chronic NB.
- Suggests a promising therapeutic avenue (low-dose methotrexate) for treatment-resistant chronic NB, potentially improving patient outcomes.